Dengue virus detection using whole blood for reverse transcriptase PCR and virus isolation
- PMID: 17522268
- PMCID: PMC1951229
- DOI: 10.1128/JCM.00305-07
Dengue virus detection using whole blood for reverse transcriptase PCR and virus isolation
Abstract
Dengue is one of the most important diseases in the tropical and subtropical regions of the world, with an estimated 2.5 billion people being at risk. Detection of dengue virus infections has great importance for the clinical management of patients, surveillance, and clinical trial assessments. Traditionally, blood samples are collected in serum separator tubes, processed for serum, and then taken to the laboratory for analysis. The use of whole blood has the potential advantages of requiring less blood, providing quicker results, and perhaps providing better sensitivity during the acute phase of the disease. We compared the results obtained by reverse transcriptase PCR (RT-PCR) with blood drawn into tubes containing EDTA and those obtained by RT-PCR with blood samples in serum separator tubes from 108 individuals clinically suspected of being infected with dengue virus. We determined that the extraction of RNA from whole blood followed by RT-PCR resulted in a higher detection rate than the use of serum or plasma. Using a selection of these samples, we also found that our ability to detect virus by direct C6/36 cell culture and mosquito inoculation was enhanced by using whole blood but not to the same extent as that seen by the use of RT-PCR.
Figures
References
-
- Chanthavanich, P., C. Luxemburger, C. Sirivichayakul, K. Lapphra, K. Pengsaa, S. Yoksan, A. Sabchareon, and J. Lang. 2006. Short report: immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am. J. Trop. Med. Hyg. 75:26-28. - PubMed
-
- De Paula, S. O., and B. A. Lopes da Fonseca. 2002. Optimizing dengue diagnosis by RT-PCR in IgM-positive samples: comparison of whole blood, buffy-coat and serum as clinical samples. J. Virol. Methods 102:113-117. - PubMed
-
- Durbin, A. P., S. S. Whitehead, J. McArthur, J. R. Perreault, J. E. Blaney, Jr., B. Thumar, B. R. Murphy, and R. A. Karron. 2005. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191:710-718. - PubMed
-
- Edelman, R., S. S. Wasserman, S. A. Bodison, R. J. Putnak, K. H. Eckels, D. Tang, N. Kanesa-Thasan, D. W. Vaughn, B. L. Innis, and W. Sun. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69:48-60. - PubMed
-
- Endy, T. P., S. Chunsuttiwat, A. Nisalak, D. H. Libraty, S. Green, A. L. Rothman, D. W. Vaughn, and F. A. Ennis. 2002. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am. J. Epidemiol. 156:40-51. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
